Pediatrics

The day will be held on October 10. It is coordinated by the International Agency for the Prevention of Blindness under the “Love Your Eyes” campaign banner, and is putting children at the center of the campaign.

CN6 palsy from the COVID-19 virus is rare, and can occur in infants as young as 7 months.

Researchers from the Shanghai Jiao Tong University School of Medicine developed a deep learning–based model for early identification of myopia, strabismus, and ptosis using 1419 facial photographs from 476 individuals.

According to the company, VCN-01, its lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. The FDA had previously granted orphan drug designation to VCN-01 for treatment of retinoblastoma.

Prevent Blindness provides opportunities for awareness and action in support of new legislation to provide much-needed funding for children’s vision programs in the United States.

The approach to treating amblyopia in young children couples proprietary therapeutic software with virtual reality (VR) headsets and popular children's TV shows

NVK002 atropine 0.01% (Vyluma Inc.) “meaningfully slowed” myopia progression in myopic pediatric patients over a 36-month period.

The Type A meeting addressed questions the FDA had about the late-stage product candidate

Low birth weight, blood transfusion, necrotising enterocolitis, bronchopulmonary dysplasia and antenatal steroid and surfactant therapies are among the factors that affect the development of ROP.

Data from the trial found that MyopiaX proved clinically safe and tolerable, in addition to showing clinical effect on the rate of myopia progression.

The Early Detection of Vision Impairment in Children (EDVI) Act would establish the first federal program to address children’s vision and eye health.

New research findings presented at this year's ARVO meeting compare two groups of paediatric patients in Nepal

Researchers examined disparities in service coverage of pediatric ophthalmologists and pediatric optometrists in relation to patient demographics to cast a light on at-risk populations and provide data for future decisions.

Early keratoconus screening advocated

Evaluating injections of anti-VEGF drugs into the intra-anterior chamber may be a viable alternative, but further study is required.

Siloam Vision and Orbis team up to develop infrastructure to save the vision of premature infants.

According to the company, MicroPine, currently in late phase III for pediatric progressive myopia, will complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007.

The first step in management is increasing the time spent outside

Analysis showed low-dose, preservative-free formulation of atropine is effective in slowing progression in children aged 3 to 17, living in the US and European Union.

According to data presented at the American Academy of Ophthalmology annual meeting in San Francisco, a study of children with cell disease finds 1 in 3 had retinopathy.

The collaboration, fueled by a $5 million donation from Knights Templar Eye Foundation (KTEF), will introduce a free and open VR simulation program for ophthalmologists and trainees worldwide.

OCT and OCTA imaging were especially valuable in this patient population because the images extended the current definition of sickle cell retinopathy.

The FDA has granted temporary discretion to import erythromycin ophthalmic ointment for the treatment of newborns.

Polish researchers found positive bacterial cultures in premature infants correlated with severe retinopathy of prematurity (ROP), suggesting a potential prognostic marker for early ROP development.

NVK002 is currently under FDA review, with a PDUFA date scheduled for January 31, 2024.

The MyopiaX-1 trial studies MyopiaX, a smartphone application that aims to slow the progression of myopia, or nearsightedness, in children and adolescents.

Efficacy of treatment option is also confirmed in pediatric population in India.

According to the companies, the partnership will roll out a proprietary system that has earned FDA breakthrough designation, one of the few ophthalmic devices to achieve this status in almost a decade.